Medicine and Dentistry
Overall Survival
88%
Meta-Analysis
88%
Neoplasm
84%
Surgery
74%
Malignant Neoplasm
66%
Systematic Review
58%
Esophageal Cancer
51%
Stomach Cancer
49%
Lymph Node
42%
Esophagectomy
38%
Disease
35%
Transcatheter Arterial Chemoembolization
35%
Pancreaticoduodenectomy
35%
Odds Ratio
29%
Pancreas Cancer
29%
Neoadjuvant Chemotherapy
28%
Chemoradiotherapy
28%
Hepatocellular Carcinoma
28%
Pancreas Adenocarcinoma
25%
Breast Cancer
24%
Recurrent Disease
22%
Radiation Therapy
22%
Retroperitoneal Lymph Node Dissection
21%
Distal Pancreatectomy
21%
Stomach Paresis
21%
Metastatic Carcinoma
20%
Liver Metastasis
17%
Pylorus
16%
Quality of Life
16%
Colorectal Carcinoma
15%
Mastectomy
14%
Adrenal Cortex Carcinoma
14%
Minimally Invasive Surgery
14%
Peritoneum Metastasis
14%
Radioembolization
14%
Plummer-Vinson Syndrome
14%
Long Term Survival
13%
Hazard Ratio
12%
Contralateral
11%
Symptomatic Treatment
11%
Randomized Controlled Trial
11%
Gastrectomy
10%
Injury
10%
Pancreas Fistula
10%
Socioeconomic Status
9%
Targeted Therapy
9%
Interventional Radiology
9%
Sentinel Lymph Node Biopsy
9%
Preventive Mastectomy
9%
Surgeon
9%
Keyphrases
Meta-analysis
100%
Overall Survival
89%
Confidence Interval
68%
Systematic Meta-analysis
56%
Odds Ratio
42%
Pancreaticoduodenectomy
42%
Esophageal Cancer
39%
Resection
36%
Tumor
29%
Esophagectomy
29%
Transarterial Chemoembolization
28%
Gastric Cancer
28%
Cancer Patients
26%
Neoadjuvant Chemotherapy
26%
Pancreatic Ductal Adenocarcinoma
24%
Chemotherapy
23%
Delayed Gastric Emptying
21%
Risk Ratio
21%
Minimally Invasive
18%
Neoadjuvant Chemoradiotherapy (nCRT)
18%
Advanced Esophageal Cancer
17%
Surgical Resection
17%
Hazard Ratio
16%
Long-term Survival
16%
Preoperative Chemotherapy
15%
National Cancer Database
15%
Lymph Node Sampling
15%
Pancreatic Cancer
14%
Minimally Invasive Surgery
14%
Distal Pancreatectomy
14%
Hepatocellular Carcinoma
14%
Tumor Location
14%
Chemoembolization
14%
Unresectable Hepatocellular Carcinoma
14%
Regional Lymph Nodes
14%
Radioembolization
14%
Gastric Cancer Patients
14%
Pathological Complete Response
14%
Tumor Analysis
14%
Orthogonal Analysis
14%
Malignant Dysphagia
14%
Peritoneal Metastasis
14%
Adrenocortical Carcinoma
14%
Metastatic Disease
13%
Pylorus-preserving Pancreaticoduodenectomy
13%
Improved Survival
12%
Metastatic Gastric Cancer
12%
Stent
12%
Adjuvant Chemotherapy
11%
Targeted Therapy
11%